Cephalosporins

Afix® is indicated in the treatment of the following infections caused by susceptible microorganisms: Upper respiratory tract infections: Otitis media and other URTI where the causative organism is known or suspected to be resistant to other commonly used antibiotics. Lower respiratory tract infection: Bronchitis. Urinary tract infections: Cystitis, cystourethritis, pyelonephritis, gonococcal urethritis. Gonorrhoea (Uncomplicated). Typhoid fever.

Each 5 ml contains Cefixime 100 mg

50 ml / Bot

The usual course of treatment is 7 days. This may be continued for up to 14 days if required. Afix® Powder for Suspension & DS Powder for Suspension: Children above 6 months: 8 mg/kg daily in 1-2 divided doses or 6 months-1 year: 75 mg daily 1-4 years: 100 mg daily 5-10 years: 200 mg daily Typhoid fever: 20 mg/kg body weight daily in 2 divided doses for 10 days

Cefixime is contraindicated in patients with known hypersensitivity to the cephalosporin antibiotics.

Afix® is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature. Gastro-intestinal disturbances: Diarrhoea (if severe diarrhoea occurs, Afix® should be discontinued), changes in the color of stool, nausea, abdominal pain, dyspepsia, vomiting, flatulence have been reported. Central nervous system disturbances: Headache, dizziness etc. Others: Hypersensitivity reactions which usually subsided upon discontinuation of therapy; infrequent and reversible haematological changes; elevation of serum amylase etc.

Carbamazepine: Elevated carbamazepine levels have been reported. Warfarin and Anticoagulants: Increased prothrombin time with or without clinical bleeding has been reported when cefixime is administered concomitantly.

Aristopharma Ltd., Bangladesh.